~~<i id='6BBE02EE9F'><strike id='6BBE02EE9F'><tt id='6BBE02EE9F'><pre id='6BBE02EE9F'></pre></tt></strike></i>~~

Home» knowledge» comprehensive

comprehensive

author：focus 2025-09-29 09:57:20 Page View：42

Editor’s note: A recording of the event is embedded below.

After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

Featured Speakers

Irena Melnikova, Ph.D., partner, Pfizer Ventures
Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cognito secures funding to test medical device for Alzheimer's
Next article： Affirmative action in medical school literally saved lives

explore

Malaria cases in Florida and Texas: Here’s what you need to know

MosquitoscaughtfortestingawaitshipmenttoalabinMcAllen,Texas,inApril2016tobetestedformosquito-bornedi

The real point of Kenneth Smith’s execution by nitrogen gas

Alabama'slethalinjectionchamberatHolmanCorrectionalFacilityinAtmore.APOnThursdayevening,thestateofAl

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

Commercial surrogacy can be ethical, despite pope’s claims

AdobeOverthepastfewyears,IhavewatchedawonderfulyoungboyI’llcallChadgrowupsmartandfulloflife.Hisparen